Project Grant R21AI189372
Award Date
4/9/25
Completion Date
3/31/27
Dollars Obligated
$236K
Federal Agency
National Institute of Allergy and Infectious Diseases
Federal Grant Program
93.855
Assistance Type
Project Grant
Place of Performance
New Jersey, USA
Similar Awards
The National Institute of Allergy and Infectious Diseases (NIAID), under the Trans-NIH Research Support program (CFDA 93.310), has awarded a $149,008 Cooperative Agreement to Cartesian Therapeutics Inc. to develop and test a novel RNA-engineered chimeric antigen receptor (CAR) T cell therapy, named Descartes-08, for the treatment of systemic lupus erythematosus (SLE). The project aims to finalize the design and operating procedures for a Phase 2B randomized, placebo-controlled clinical trial...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $793,093 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to the Oklahoma Medical Research Foundation to study the genetic and regulatory mechanisms underlying the relationship between systemic lupus erythematosus (SLE) and cardiovascular disease. The project aims to identify regulatory variants and target genes in macrophages that are disrupted by SLE risk alleles, which may...
This Project Grant award, with a total funding amount of $2,902,477.00, was provided by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855). The award will support a 5-year research program titled "Learning from Remission and Relapse in SLE" that aims to study the immune profiles and brain function of systemic lupus erythematosus (SLE) patients in long-term clinical remission. Key research activities...
The University of Washington received a $256,808 Project Grant Award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855). The grant, which runs from March 2025 to February 2027, will support research to better define the molecular mechanisms that cause and perpetuate systemic lupus erythematosus (SLE). The researchers will analyze altered mRNA splicing in SLE neutrophils, explore the consequences of...
This federal Project Grant award for $173,556, provided by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), supports research to delineate the role of retroelements in the pathogenesis of systemic lupus erythematosus (SLE). The grant recipient, Yale University, will (1) characterize gene and retroelement expression patterns as well as inflammatory cytokine levels in the peripheral blood and skin of SLE...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $1,622,956.00 to the Benaroya Research Institute at Virginia Mason to study the role of IgA autoantibodies and plasmacytoid dendritic cells in the pathogenesis of systemic lupus erythematosus (SLE). The research aims to determine the mechanisms by which IgA autoantibodies and immune complexes enhance type I...
The University of Washington received a $1,517,519 Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855). The project, titled "Upstream Drivers of Type I Interferons in Lupus," aims to identify the molecular pathways that drive the chronic production of type I interferons, which play a key role in the pathogenesis of systemic lupus erythematosus (SLE). The project involves a...
This Project Grant award from the National Institutes of Health's National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research) provides $555,774 in funding to the University of Alabama at Birmingham (UAB) from November 2024 to October 2029. The project aims to investigate two key questions: 1) Whether interleukin-4 (IL-4) acts through the aryl hydrocarbon receptor (AhR) pathway to inhibit the development of double negative 2 (DN2) B cells, and 2)...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $895,140 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to Progentec Diagnostics Inc. The grant supports the validation and commercialization of two innovative diagnostic tests - the Lupus Flare Risk Index (L-FRI) and the Lupus Disease Activity Index (L-DAI). These tests leverage immunological biomarkers to proactively identify and manage heightened disease activity and clinical...
This $600,000 project grant from the National Institute of Allergy and Infectious Diseases will support General Nanotherapeutics LLC's development of nanoimmunotherapy for chronic immune-mediated diseases. The company will leverage nanoparticles to target and expand immunoregulatory cells ex vivo and assess their ability to suppress effector immune responses and induce remission in vivo, including in a lupus model. This proof-of-concept work aligns with the Allergy and Infectious Diseases...